Latest Breaking News On - Mamoru watanabe - Page 1 : comparemela.com

The cell processing center operates advanced cell therapy

Step in the compact CPC (Cell Processing Center) and discover its processes and the technology it uses to achieve advanced cell therapy and regenerative therapy.

Japan generalLouis castelTomohiro morioMichiko kajiwaraMamoru watanabeIchiro sekiyaEuropeb vdecMari kannagiCell processing centerHoldings corporationCenter blood infusionRegenerative therapy research center gastrointestinal departmentCell therapy centerRegenerative therapy research center orthopedicsSponsored contentBlood infusion

World s first-in-human research using organoid transplantation yields good results

Tokyo Medical and Dental University (TMDU) research team announced on July 7 that it has succeeded in the world's first clinical transplantation of a "mini organ (also called Organoid)" into a patient with "Ulcerative Colitis (UC)".

Ryuichi okamotoMamoru watanabeEmily hendersonDepartment of gastroenterologyTokyo medical dental universityDental universityBowel diseaseTokyo medicalGraduate schoolDental sciencesUlcerative colitis

Announcement about an approval for additional indication of Jyseleca, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapies

Gilead Sciences K.K.(Headquarter: Chiyoda-ku, Tokyo, General Manager: Kennet Brysting, “Gilead”), Eisai Co., Ltd.

Bunkyo kuUnited kingdomJapan generalChuo kuUnited statesChiyoda kuFoster cityGreat britainNorifumi hibiHaruo naitoMamoru watanabeHidenori yabuneKennet brystingEisai co ltdEa pharma co ltdGilead sciences

acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

Japan generalNorifumi hibiMamoru watanabeEisai co ltdEa pharma co ltdGilead sciencesAnnouncement aboutAdditional indicationJanus kinaseAdvanced treatmentInflammatory bowel diseaseKitasato institute hospitalTokyo medicalDental universityAcn newswire

Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor

Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor
jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.

Japan generalNorifumi hibiMamoru watanabeEisai co ltdEa pharma co ltdGilead sciencesJapan corporate news networkAnnouncement aboutAdditional indicationJanus kinaseAdvanced treatmentInflammatory bowel diseaseKitasato institute hospitalTokyo medicalDental universityJapan corporate news